Research ExplorerPublicationsNovel Approaches for BAV Aortopathy Prediction-Is There a Ne...

Novel Approaches for BAV Aortopathy Prediction-Is There a Need for Cohort Studies and Biomarkers?

Standard

Novel Approaches for BAV Aortopathy Prediction-Is There a Need for Cohort Studies and Biomarkers? / Girdauskas, Evaldas; Petersen, Johannes; Neumann, Niklas; Naito, Shiho; Gross, Tatiana; Jagodzinski, Annika; Reichenspurner, Hermann; Zeller, Tanja.

In: BIOMOLECULES, Vol. 8, No. 3, 19.07.2018.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Girdauskas, E, Petersen, J, Neumann, N, Naito, S, Gross, T, Jagodzinski, A, Reichenspurner, H & Zeller, T 2018, 'Novel Approaches for BAV Aortopathy Prediction-Is There a Need for Cohort Studies and Biomarkers?', BIOMOLECULES, vol. 8, no. 3. https://doi.org/10.3390/biom8030058

APA

Girdauskas, E., Petersen, J., Neumann, N., Naito, S., Gross, T., Jagodzinski, A., Reichenspurner, H., & Zeller, T. (2018). Novel Approaches for BAV Aortopathy Prediction-Is There a Need for Cohort Studies and Biomarkers? BIOMOLECULES, 8(3). https://doi.org/10.3390/biom8030058

Vancouver

Girdauskas E, Petersen J, Neumann N, Naito S, Gross T, Jagodzinski A et al. Novel Approaches for BAV Aortopathy Prediction-Is There a Need for Cohort Studies and Biomarkers? BIOMOLECULES. 2018 Jul 19;8(3). https://doi.org/10.3390/biom8030058

Bibtex

@article{d8ac15c783bc40a7858ff7b7419f1e42,
title = "Novel Approaches for BAV Aortopathy Prediction-Is There a Need for Cohort Studies and Biomarkers?",
abstract = "Bicuspid aortic valve (BAV) disease is the most common congenital malformation of the human heart with a prevalence of 1⁻2% in the general population. More than half of patients with a BAV present with a dilated proximal aorta (so-called bicuspid aortopathy) which is associated with an enhanced risk of life-threatening aortic complications. Up to now, the pathogenesis of bicuspid aortopathy as well as the risk stratification of aortic complications has not yet been sufficiently clarified. Recent findings have shown that bicuspid aortopathy features phenotypic heterogeneity. Two distinct valvulo-aortic phenotypes, the so-called root phenotype, as well as a dilation of the tubular ascending aorta, coincide with a significantly different risk for aortal complications. However, the phenotype-based classification that is only based on these two clinical forms is not sufficient to estimate the risk of aortal complications in a prognostically relevant way. Therefore, there is growing clinical interest to assess novel approaches in BAV research and to introduce circulating biomarkers as an elegant diagnostic tool to improve risk stratification in BAV aortopathy. A large scale epidemiological cohort study, ranking from apparently healthy individuals to disease patients, and comprehensive biobanks provide the opportunity to study BAV disease and its complications and to identify novel biomarkers for BAV aortopathy surveillance and prognosis. Firstly, the data indicate that several protein-based biomarkers and non-coding RNA molecules, in particular circulating microRNAs, can serve as relevant molecular biomarkers to predict the course of BAV-associated aortopathy. Here, we review the current literature and knowledge about BAV from a clinical point of view, and report about novel approaches in BAV biomarker research.",
keywords = "Aortic Diseases/diagnosis, Aortic Valve/abnormalities, Bicuspid Aortic Valve Disease, Biomarkers/blood, Early Diagnosis, Heart Valve Diseases/pathology, Humans, MicroRNAs/blood, Phenotype, Population Surveillance, Prognosis",
author = "Evaldas Girdauskas and Johannes Petersen and Niklas Neumann and Shiho Naito and Tatiana Gross and Annika Jagodzinski and Hermann Reichenspurner and Tanja Zeller",
year = "2018",
month = jul,
day = "19",
doi = "10.3390/biom8030058",
language = "English",
volume = "8",
journal = "BIOMOLECULES",
issn = "2218-273X",
publisher = "Multidisciplinary Digital Publishing Institute",
number = "3",

}

RIS

TY - JOUR

T1 - Novel Approaches for BAV Aortopathy Prediction-Is There a Need for Cohort Studies and Biomarkers?

AU - Girdauskas, Evaldas

AU - Petersen, Johannes

AU - Neumann, Niklas

AU - Naito, Shiho

AU - Gross, Tatiana

AU - Jagodzinski, Annika

AU - Reichenspurner, Hermann

AU - Zeller, Tanja

PY - 2018/7/19

Y1 - 2018/7/19

N2 - Bicuspid aortic valve (BAV) disease is the most common congenital malformation of the human heart with a prevalence of 1⁻2% in the general population. More than half of patients with a BAV present with a dilated proximal aorta (so-called bicuspid aortopathy) which is associated with an enhanced risk of life-threatening aortic complications. Up to now, the pathogenesis of bicuspid aortopathy as well as the risk stratification of aortic complications has not yet been sufficiently clarified. Recent findings have shown that bicuspid aortopathy features phenotypic heterogeneity. Two distinct valvulo-aortic phenotypes, the so-called root phenotype, as well as a dilation of the tubular ascending aorta, coincide with a significantly different risk for aortal complications. However, the phenotype-based classification that is only based on these two clinical forms is not sufficient to estimate the risk of aortal complications in a prognostically relevant way. Therefore, there is growing clinical interest to assess novel approaches in BAV research and to introduce circulating biomarkers as an elegant diagnostic tool to improve risk stratification in BAV aortopathy. A large scale epidemiological cohort study, ranking from apparently healthy individuals to disease patients, and comprehensive biobanks provide the opportunity to study BAV disease and its complications and to identify novel biomarkers for BAV aortopathy surveillance and prognosis. Firstly, the data indicate that several protein-based biomarkers and non-coding RNA molecules, in particular circulating microRNAs, can serve as relevant molecular biomarkers to predict the course of BAV-associated aortopathy. Here, we review the current literature and knowledge about BAV from a clinical point of view, and report about novel approaches in BAV biomarker research.

AB - Bicuspid aortic valve (BAV) disease is the most common congenital malformation of the human heart with a prevalence of 1⁻2% in the general population. More than half of patients with a BAV present with a dilated proximal aorta (so-called bicuspid aortopathy) which is associated with an enhanced risk of life-threatening aortic complications. Up to now, the pathogenesis of bicuspid aortopathy as well as the risk stratification of aortic complications has not yet been sufficiently clarified. Recent findings have shown that bicuspid aortopathy features phenotypic heterogeneity. Two distinct valvulo-aortic phenotypes, the so-called root phenotype, as well as a dilation of the tubular ascending aorta, coincide with a significantly different risk for aortal complications. However, the phenotype-based classification that is only based on these two clinical forms is not sufficient to estimate the risk of aortal complications in a prognostically relevant way. Therefore, there is growing clinical interest to assess novel approaches in BAV research and to introduce circulating biomarkers as an elegant diagnostic tool to improve risk stratification in BAV aortopathy. A large scale epidemiological cohort study, ranking from apparently healthy individuals to disease patients, and comprehensive biobanks provide the opportunity to study BAV disease and its complications and to identify novel biomarkers for BAV aortopathy surveillance and prognosis. Firstly, the data indicate that several protein-based biomarkers and non-coding RNA molecules, in particular circulating microRNAs, can serve as relevant molecular biomarkers to predict the course of BAV-associated aortopathy. Here, we review the current literature and knowledge about BAV from a clinical point of view, and report about novel approaches in BAV biomarker research.

KW - Aortic Diseases/diagnosis

KW - Aortic Valve/abnormalities

KW - Bicuspid Aortic Valve Disease

KW - Biomarkers/blood

KW - Early Diagnosis

KW - Heart Valve Diseases/pathology

KW - Humans

KW - MicroRNAs/blood

KW - Phenotype

KW - Population Surveillance

KW - Prognosis

U2 - 10.3390/biom8030058

DO - 10.3390/biom8030058

M3 - SCORING: Review article

C2 - 30029528

VL - 8

JO - BIOMOLECULES

JF - BIOMOLECULES

SN - 2218-273X

IS - 3

ER -